

1 **Exposure to diphtheria toxin during the juvenile period impairs both inner**
2
3 **and outer hair cells in C57BL/6 mice**
4
5
6
7

8 Hiroyuki Konishi^a, Nobutaka Ohgami^{b,c}, Aika Matsushita^a, Yuki Kondo^a, Yuki Aoyama^d,
9
10 Masaaki Kobayashi^a, Taku Nagai^d, Shinya Ugawa^e, Kiyofumi Yamada^d, Masashi Kato^b,
11
12
13 Hiroshi Kiyama^a
14
15
16
17
18

19 ^aDepartment of Functional Anatomy and Neuroscience, Nagoya University Graduate School of
20
21 Medicine, Nagoya, 466-8550, Japan
22
23

24 ^bDepartment of Occupational and Environmental Health, Nagoya University Graduate School
25
26 of Medicine, Nagoya, 466-8550, Japan
27
28

29 ^cNutritional Health Science Research Center, Chubu University, Kasugai, 487-8501, Japan
30
31

32 ^dDepartment of Neuropsychopharmacology and Hospital Pharmacy, Nagoya University
33
34 Graduate School of Medicine, Nagoya, 466-8550, Japan
35
36

37 ^eDepartment of Anatomy and Neuroscience, Graduate School of Medical Sciences, Nagoya
38
39 City University, Nagoya, 467-8601, Japan
40
41
42
43
44

45 **E-mail addresses:**
46

47 Hiroyuki Konishi: konishi@med.nagoya-u.ac.jp
48
49

50 Nobutaka Ohgami: nobugami@med.nagoya-u.ac.jp
51
52

53 Aika Matsushita: aika.mat@hotmail.co.jp
54
55

56 Yuki Kondo: kondogagigugego@gmail.com
57
58

59 Yuki Aoyama: y.aoyama1007@gmail.com
60
61
62
63
64
65

1 Masaaki Kobayashi: 4444.forum@gmail.com

2
3 Taku Nagai: t-nagai@med.nagoya-u.ac.jp

4
5
6 Shinya Ugawa: ugawa@med.nagoya-cu.ac.jp

7
8
9 Kiyofumi Yamada: kyamada@med.nagoya-u.ac.jp

10
11 Masashi Kato: katomasa@med.nagoya-u.ac.jp

12
13
14 Hiroshi Kiyama: kiyama@med.nagoya-u.ac.jp

15
16
17
18
19 **Corresponding author:**

20
21 Hiroyuki Konishi or Hiroshi Kiyama, Department of Functional Anatomy and Neuroscience,

22
23
24 65 Tsurumai-cho, Showa-ku, Nagoya 466-8550, Japan, Tel.: +81-52-744-2015, Fax:

25
26
27 +81-52-744-2027, E-mail: konishi@med.nagoya-u.ac.jp, kiyama@med.nagoya-u.ac.jp

1 **Abbreviations:**

2
3 ABR, auditory brainstem response

4
5
6 DT, diphtheria toxin

7
8 DTR, DT receptor

9
10 EDTA, ethylenediaminetetraacetic acid

11
12
13 EF-2, elongation factor-2

14
15
16 HB-EGF, heparin-binding epidermal growth factor-like growth factor

17
18
19 HC, hair cell

20
21 H&E, hematoxylin and eosin

22
23
24 IHC, inner hair cell

25
26
27 OHC, outer hair cell

28
29 P, postnatal

30
31 PB, phosphate buffer

32
33
34 PBS, phosphate-buffered saline

35
36
37 PFA, paraformaldehyde

38
39
40 SEM, scanning electron microscopy

41
42
43 SGN, spiral ganglion neuron

44
45 SPL, sound pressure level

46
47
48 SV, stria vascularis

49
50
51 TNBT, tetranitro blue tetrazolium

52
53
54 W, week-old

55
56 WT, wildtype

1 **ABSTRACT**

2
3 Diphtheria toxin (DT) administration into transgenic mice that express the DT receptor (DTR)
4
5 under control of specific promoters is often used for cell ablation studies *in vivo*. Because DTR
6
7 is not expressed in mice, DT injection has been assumed to be nontoxic to cells *in vivo*. In this
8
9 study, we demonstrated that DT application during the juvenile stage leads to hearing loss in
10
11 wildtype mice. Auditory brainstem response measurement showed severe hearing loss in
12
13 C57BL/6 mice administered DT during the juvenile period, and the hearing loss persisted into
14
15 adulthood. However, ototoxicity did not occur when DT was applied on postnatal day 28 or
16
17 later. Histological studies demonstrated that hearing loss was accompanied by significant
18
19 degeneration of inner and outer hair cells (HCs), as well as spiral ganglion neurons. Scanning
20
21 electron microscopy showed quick degeneration of inner HCs within 3 days and gradual
22
23 degeneration of outer HCs within 1 week. These results demonstrated that DT has ototoxic
24
25 action on C57BL/6 mice during the juvenile period, but not thereafter, and the hearing loss was
26
27 due to degeneration of inner and outer HCs by unknown DT-related mechanisms.
28
29
30
31
32
33
34
35
36
37
38
39

40 **Keywords:** cochlea; degeneration; diphtheria toxin; hair cell; hearing loss; ototoxicity
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1 Conditional ablation of specific cells is an indispensable technique for studying cellular
2
3 functions *in vivo*. In recent studies, transgenic or knock-in mice, which are designed to express
4
5 diphtheria toxin (DT) receptor (DTR) in a specific cell-type, have been used for conditional
6
7 ablation studies (Saito et al., 2001). DT is an exotoxin secreted by *Corynebacterium*
8
9 *diphtheriae*. After binding to DTR, which is identical to human heparin-binding epidermal
10
11 growth factor-like growth factor (HB-EGF) (Naglich et al., 1992), DT is translocated to
12
13 endosomes by endocytosis, and the A-fragment of DT is released into the cytoplasm (Collier
14
15 and Kandel, 1971; Gill and Dinius, 1971; Dorland et al., 1979). The released A-fragment then
16
17 catalyzes ADP-ribosylation of elongation factor-2 (EF-2) and inhibits protein synthesis,
18
19 thereby inducing cell death (Honjo et al., 1968; Robinson et al., 1974). The DT-induced
20
21 ablation system in mice is based on the fact that DT binds to human HB-EGF but not to mouse
22
23 HB-EGF (Mitamura et al., 1995; Cha et al., 1998). Mice have been shown to be resistant to DT
24
25 (Pappenheimer et al., 1982), and conditional ablation of specific cells, which exogenously
26
27 express DTR, is achieved by systemic administration of DT (Saito et al., 2001).
28
29
30
31
32
33
34
35
36
37
38
39

40 Because DT itself is assumed to have no biological effect on wildtype (WT) mice, several
41
42 studies failed to include a control group that treated WT mice with DT in their study (Kwon et
43
44 al., 2014; Wang et al., 2014). Conversely, some studies have reported unexpected off-target
45
46 effects of DT on WT mice, such as weight loss (Meyer Zu Horste et al., 2010; Goldwich et al.,
47
48 2012; Christiaansen et al., 2014), proteinuria (Goldwich et al., 2012), and mucosal
49
50 inflammation of the lung (Chapman and Georas, 2013). Furthermore, high-dose DT was shown
51
52 to be lethal in mice (Bonventre et al., 1973; Goldwich et al., 2012; Christiaansen et al., 2014).
53
54 Because these reports used purified DT with few contaminants, such as endotoxins, and
55
56
57
58
59
60
61
62
63
64
65

1 demonstrated consistent results using DT supplied from different vendors (Meyer Zu Horste et
2 al., 2010; Chapman and Georas, 2013; Christiaansen et al., 2014), these studies demonstrated
3 that DT causes adverse effects on mice.
4
5
6
7
8
9

10 In an analysis using DTR knock-in mice from the C57BL/6 strain, results unexpectedly showed
11 that DT-treated juvenile mice exhibited abnormal behaviors in response to auditory stimuli, and
12 this abnormality was also observed in C57BL/6 WT mice. Therefore, we hypothesized that DT
13 might induce side effects, such as hearing loss. In the present study, we investigated the effects
14 of DT during postnatal development, and results revealed that inner hair cells (IHCs), outer hair
15 cells (OHCs), and spiral ganglion neurons (SGNs) were impaired after DT treatment, and
16 juvenile C57BL/6 mice were more susceptible to DT.
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

EXPERIMENTAL PROCEDURES

Animals

Male C57BL/6J and CBA/J mice were purchased from Charles River Laboratories Japan (Yokohama, Japan). All experimental procedures were conducted in accordance with standard guidelines for animal experiments from the Nagoya University Graduate School of Medicine. This study was approved by the local animal ethics committee of Nagoya University (approval number: 26181, 27204 and 28303). All efforts were made to minimize the number of animals and their suffering.

Recording of auditory brainstem response (ABR)

Phosphate-buffered saline (PBS) or DT (50 μ g/kg, Sigma, St Louis, MO, USA) was intraperitoneally injected into postnatal (P) 7, P14, P28, or 8-week-old (W) mice. Survival rates were almost 100%, and neither morphological nor behavioral abnormalities were observed after treatment with this DT dose. ABR was measured as described in our previous reports at 14 or 15 days after DT administration (AD Instruments Pty. Ltd., Castle Hill, Australia) (Ohgami et al., 2010). Tone-burst stimuli at 4, 12, 20, and 32 kHz were recorded in 10-dB increments from 0 to 90 or 100 dB sound pressure level (SPL). The threshold was determined by identifying the lowest level of wave I. When any wave was not observed at the highest stimulation level, the threshold was assigned to the highest presentation level plus 10 dB. The number of “scale-out” animals is indicated in each figure. In control mice, the thresholds were higher than previous reports, in particular at high frequency, which could be due to our ABR system setup.

Hematoxylin and eosin (H&E) staining and quantification of SGN numbers

Mice were intraperitoneally injected with PBS or DT (50 $\mu\text{g}/\text{kg}$) at P7. At P21 or P56, mice were anesthetized and perfused with 4% paraformaldehyde (PFA) in 0.1 M phosphate buffer (PB). Inner ears were dissected, post-fixed in the same fixative overnight at 4°C, and decalcified in 0.1 M PB containing 10% ethylenediaminetetraacetic acid (EDTA) for several days. The 5- μm -thick paraffin sections were cut on a microtome, deparaffinized with xylene, and then stained with H&E. After dehydration with an ascending ethanol series, sections were cleared with xylene and mounted. The number of SGNs in the apical, middle and basal turn were quantified and normalized to the spiral ganglion area. A total of 9 sections from 3 animals (3 sections per animal) were analyzed at each time point. The interval of each section was at least 30 μm , and there was no possibility of double-counting the same cells.

Whole-mount tetranitro blue tetrazolium (TNBT) staining of the cochlea

Mice were intraperitoneally injected with PBS or DT (50 $\mu\text{g}/\text{kg}$) at P7 and HC numbers were analyzed at P21. TNBT staining of cochlea was performed in accordance with a previous report (Wang et al., 2011). Briefly, cochleae were dissected and incubated in a staining solution containing sodium succinate and TNBT for 45 min at 37°C. After fixation with 10% formalin, the bone was carefully removed from the apex using fine forceps, and images of the HC surface were taken by a stereoscopic microscope M60 (Leica Microsystems, Wetzlar, Germany) at the apical, middle, and basal turn. The number of IHCs and OHCs were quantified in each turn and normalized to the length of the basilar membrane. Five animals were analyzed in total.

Scanning electron microscopy (SEM)

1 Mice intraperitoneally injected with PBS or DT (50 $\mu\text{g}/\text{kg}$) at P7 were analyzed by SEM at P8,
2
3 10, 14, and 21. After decapitation, the inner ear was dissected and immediately immersed in a
4
5 fixative (30 mM HEPES, pH 7.4, 5% glutaraldehyde, 10% PFA, 100 mM NaCl, 2 mM CaCl_2).
6
7
8 The cochleae were perfused with the fixative, post-fixed in the same fixative for 1 week, and
9
10 decalcified in 0.1 M PB (pH 6.6) containing 8% EDTA, 4% PFA, and 10% sucrose for at least 3
11
12 days. Then the cochleae were processed using the osmium tetroxide and thiocarbohydrazide
13
14 method (Hunter-Duvar, 1978). After dehydration with a critical point dryer (EM CPD300,
15
16 Leica Microsystems), images of the middle turn were taken by an electron microscope
17
18 (JSM-7610F, JEOL Ltd, Tokyo, Japan) with a magnification of 2,000 \times or 15,000 \times . At least
19
20 three animals were analyzed and representative images are shown.
21
22
23
24
25
26
27
28

29 **Statistical analyses**

30 Values are expressed as mean \pm S.E.M. Data were analyzed using Student's *t*-test, and $P < 0.05$
31
32 was considered statistically significant.
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

RESULTS

Hearing impairment is observed in C57BL/6 WT mice treated with DT during the juvenile period

We intraperitoneally injected DT into P7 C57BL/6 WT mice at a dose of 50 $\mu\text{g}/\text{kg}$. The same or a greater dose was generally used to ablate DTR-expressing cells in the brain *in vivo* (Knowlton et al., 2013; Parkhurst et al., 2013; Pedersen et al., 2013). Survival rates were nearly 100%, and visible morphological or behavioral abnormalities were not observed after DT treatment.

However, severe hearing loss developed in the DT-treated mice at P21 (14 days after DT administration) (Fig. 1A and B). ABR measurements, which recorded electrical signals evoked from the brainstem by sound stimuli, demonstrated that ABR thresholds were significantly greater in DT-treated mice at all frequencies. To examine the possibility that hearing impairment was transient, the same mice were allowed to mature to adult (8W) and the ABR test was repeated (Fig. 1C). Hearing loss was consistently observed in the adult mice, suggesting that the hearing loss was permanent.

In several previous studies using DT, behavioral tests, such as fear conditioning and pre-pulse inhibition that uses sound, were normal in DT-treated mice (Han et al., 2009; Xu et al., 2015).

Because those studies used adult mice, we hypothesized that DT-induced hearing loss might depend on the developmental stage at DT administration. Therefore, we injected DT into C57BL/6 mice at P14, P28, and adult (8W), and measured ABR at 14 or 15 days after injection (Fig. 2). Similar or more severe hearing loss was also observed in P14-administrated mice (Fig. 2A). When we applied DT at P28, hearing levels slightly declined. However, the decreased level was not statistically significant at all frequencies (Fig. 2B). The ABR threshold after DT

1 administration at 8W showed comparable patterns with the vehicle-injected mice (Fig. 2C).

2
3 These results indicated that juvenile mice were more susceptible to damage, and suggested the
4
5 existence of a developmental time window in DT-induced hearing loss. For subsequent studies,
6
7 we analyzed WT mice that were administered DT at P7.
8
9

10 11 12 13 **Loss of SGNs and HCs in DT-treated C57BL/6 mice**

14
15 To investigate the cause of hearing loss, we first tested H&E staining on cochlear sections (Fig.
16
17 3A). C57BL/6 mice administrated DT at P7 were analyzed at P21 and 8W. We found that the
18
19 SGN density in DT-administrated mice was less in all turns of the cochlear, although no
20
21 statistical significance was detected in the apical turn at 8W (Fig. 3A and B). Concomitant loss
22
23 of IHCs and OHCs was evident in many sections in the DT-administrated group (Fig. 3A). To
24
25 confirm HC loss, we performed whole-mount staining of cochleae with TNBT, which labels
26
27 both IHCs and OHCs in C57BL/6 mice (Wang et al., 2011). In vehicle-injected cochlea of P21
28
29 mice, three lines of OHCs and a single line of IHCs were clearly identified; whereas in
30
31 DT-treated cochlea, discontinuous and disarrayed lines of IHCs and OHCs were observed (Fig.
32
33 3C). Statistical analysis demonstrated a significant decrease in the number of IHCs and OHCs
34
35 in the apical, middle, and basal turn of the DT-administrated group (Fig. 3D). To further analyze
36
37 HC loss, we performed SEM on the middle turn at P21, revealing significant loss of IHCs and
38
39 OHCs, while the surviving cells exhibited relatively normal hair morphology in the DT-treated
40
41 mice (Fig. 3E). Results from these histological studies suggested that SGN and HC loss might
42
43 cause hearing impairment.
44
45
46
47
48
49
50
51
52
53
54
55
56
57

58 **Time-course study of HC degeneration in C57BL/6 mice**

1 Because HC loss was apparent in P21 C57BL/6 mice administrated with DT at P7, we observed
2
3 the degeneration process of HCs in the middle turn by SEM between P7 and P21 (Fig. 4). The
4
5 HC number and morphology were normal, and there was no sign of degeneration at P8 (Fig.
6
7 4A–F). However, at P10 (Fig. 4G–L), IHCs were significantly degenerated in the DT-treated
8
9 mice (Fig. 4G, H, J and K). Additionally, several OHCs exhibited degenerative features with
10
11 disordered hair as indicated by an arrowhead (Fig. 4G, I, J and L). At P14, many OHCs and
12
13 IHCs were degenerated in the DT-treated mice (Fig. 4M–R), and the overall image was
14
15 comparable to that of P21 (Fig. 3E). These results suggested that IHCs quickly degenerated,
16
17 and a significant number of OHCs gradually degenerated, suggesting that IHCs were more
18
19 susceptible to DT toxicity than OHCs.
20
21
22
23
24
25
26
27
28

29 **DT ototoxicity in CBA/J mice**

30
31 Up to this point, we had only analyzed C57BL/6 mice (Fig. 1–4). However, C57BL/6 mice
32
33 have a homozygous mutation in the cadherin 23 gene, causing severe age-related hearing loss
34
35 owing to HC degeneration (Noben-Trauth et al., 2003). This suggested the possibility that the
36
37 ototoxic effect of DT in C57BL/6 mice is a result of accelerated age-related HC degeneration.
38
39 Therefore, we examined the CBA/J strain (Fig. 5), which does not have the genetic mutation
40
41 and is highly resistant to age-related hearing loss (Willott, 1986; Ohlemiller et al., 2010). The
42
43 CBA/J WT mice received the same dose of DT (50 µg/kg) at P7, and we subsequently evaluated
44
45 hearing ability at P21 by ABR measurements (Fig. 5A). Results showed that DT administration
46
47 also induced hearing impairment at P21, although the severity was less than in C57BL/6 mice at
48
49 lower frequencies (Fig. 1 and 2). SEM images of the middle turn at P21 showed significant
50
51 degeneration of both IHCs and OHCs (Fig. 5B), suggesting that DT ototoxicity was not due to
52
53
54
55
56
57
58
59
60
61
62
63
64
65

an increased susceptibility to age-related HC loss in C57BL/6 mice.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

DISCUSSION

Results from this study demonstrated that HCs and SGNs of C57BL/6 mice are susceptible to DT exposure particularly during the juvenile period. Administration of DT (50 μ g/kg, i.p.) caused HC and SGN degeneration in juvenile mice (Fig. 3 and 4), resulting in permanent hearing loss (Fig. 1). IHC degeneration occurred quicker and was more severe than in the OHCs (Fig. 3C–E and 4). HCs are assumed to support SGN survival by secreting neurotrophic factors (Schechterson and Bothwell, 1994; Rubel and Fritzscht, 2002), and a recent study reported that HC degeneration leads to SGN loss in neonatal mice (Tong et al., 2015). Furthermore, our histological results showed that SGN degeneration was milder even at 8W, while HC degeneration was more severe (Fig. 3). Taken together, it is likely that SGN degeneration is due to HC loss.

Because the DTR knock-in mouse strain, which we initially used, was bred onto the C57BL/6 background, we analyzed the side effect of DT in C57BL/6 mice (Fig. 1–4). The C57BL/6 mice develop severe age-related hearing loss due to a homozygous mutation in the cadherin 23 gene (Noben-Trauth et al., 2003). Therefore, we analyzed CBA/J mice (Fig. 5), which do not carry the genetic mutation (Noben-Trauth et al., 2003). Although CBA/J mice do not develop age-related hearing loss at least until 1 year of age (Ohlemiller et al., 2010), significant hearing loss (Fig. 5A) and HC degeneration (Fig. 5B) also occurred in the juvenile CBA/J mice within 14 days after DT administration, suggesting that the C57BL/6 phenotype was not due to accelerated age-related hearing loss (Fig. 5). All of the present data were collected from male mice (Fig. 1–5). However, we also examined female littermates of C57BL/6 mice in our preliminary experiment, and ABR measurements consistently showed hearing loss after DT

1 administration during the juvenile period (data not shown). These results suggested that DT
2
3 ototoxicity could be a general side effect in mice.
4
5
6
7

8 Two recent papers have shown selective IHC degeneration after systemic DT administration in
9
10 WT mice (Song et al., 2015; Tong et al., 2015), although these studies only reported the
11
12 phenomenon and did not address the details. Song et al. intraperitoneally administered DT (50
13
14 $\mu\text{g}/\text{kg}$, 3 times) into CBA/CaJ WT mice at 5W, showing a significant loss of IHCs, but intact
15
16 OHCs (Song et al., 2015). We administered DT (50 $\mu\text{g}/\text{kg}$, once) into C57BL/6 mice, which
17
18 resulted in no statistically significant differences in ABR thresholds at P28 (4W) and thereafter
19
20 (Fig. 2B and C). However, the threshold at P28 exhibited an increased tendency in the
21
22 DT-treated group (Fig. 2B). The total DT dose used in the Song et al. study was three times
23
24 higher than in our study, which could explain the HC degeneration observed at 5W in their
25
26 study. Additionally, the critical periods were slightly different between the strains. Tong et al.
27
28 also showed that only a small number of IHCs degenerated after intramuscular administration
29
30 of DT (25 $\mu\text{g}/\text{kg}$) into CBA/J WT mice at P21–P42 (Tong et al., 2015). The dose was half of the
31
32 dose used in the present study, and the timing of administration overlapped the critical period in
33
34 C57BL/6 mice (Fig. 2); these results were largely consistent with ours. In the same paper,
35
36 however, results from the neonatal mice were inconsistent (Tong et al., 2015); both OHCs and
37
38 IHCs were unaffected by intramuscular administration of DT (4 $\mu\text{g}/\text{kg}$) at P2. This discrepancy
39
40 was possibly caused by the DT dose. They used a very low dose for the P2 mice, which could
41
42 account for a lack of ototoxicity. Similarly, three additional studies reported that low-dose DT
43
44 resulted in no changes in HC morphology in the WT mice (Mahrt et al., 2013; Cox et al., 2014;
45
46 Kurioka et al., 2016). Although the DT dose could be a critical determinant of the phenotype, as
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1 previously discussed, a recent study reported conflicting results (Hu et al., 2016); they
2
3 intraperitoneally administrated DT (100 ng three times) into C57BL/6 WT mice at P1.
4
5 Although the higher dose (approximately 4 times higher than ours in total) was used in the Hu
6
7 et al. study, the HCs remained intact at 3 days after injection. Because HC degeneration onset
8
9 was between 1 and 3 days after DT administration in our experiment (Fig. 4), ototoxicity might
10
11 not have been observed when they analyzed HC morphology.
12
13
14
15
16
17
18

19 In a DT-induced ablation system using DTR (human HB-EGF) transgenic or knock-in mice, the
20
21 initial binding of DT to exogenously expressed human HB-EGF is essential, because DT is
22
23 assumed to have a very low affinity for mouse HB-EGF (Mitamura et al., 1995; Cha et al.,
24
25 1998). Although it remains unclear why DT induces HC loss, several possibilities can be raised.
26
27 Given that DT directly binds to and kills HCs, a binding partner is necessary. Results from the
28
29 present study indicate that DT is toxic to mouse HCs in a human HB-EGF non-mediated
30
31 manner. Therefore, it is likely that another receptor, which has a higher affinity to DT and is
32
33 expressed by HCs, exists. To examine the possibility of direct binding of DT to HCs, we
34
35 preliminarily attempted to utilize a previously described organ culture system (data not shown)
36
37 (Parker et al., 2010). We isolated the organ of Corti from P7 mice, and cultured the organ with
38
39 high concentrations of DT. The number of HCs remained unchanged between control and
40
41 DT-treated groups, even after 7 days *in vitro*, suggesting that DT may not directly bind to
42
43 receptors on HCs. Thus, HC degeneration may be due to an indirect effect of DT.
44
45
46
47
48
49
50
51
52
53
54
55

56 Some possibilities should be considered with regard to an indirect effect of DT. Because an
57
58 impaired endolymphatic system, for instance, causes HC degeneration and occurs in Meniere's
59
60
61
62
63
64
65

1 disease (Nakashima et al., 2016), it is possible that DT may damage the stria vascularis (SV)
2
3 where the endolymph is produced (Patuzzi, 2011). However, we did not observe any SV
4
5 damages in our preliminary experiments (data not shown). We examined the integrity of the
6
7 blood-endolymph barrier in the SV at P10 using a transcardial injection of Evans blue dye,
8
9 which is known to leak after barrier disruption (Zhang et al., 2012). However, we did not detect
10
11 any extravasation of dye. Furthermore, the number and morphology of perivascular
12
13 macrophages, which are in close contact with capillaries within the SV and become activated
14
15 along with blood-endolymph barrier dysfunction (Zhang et al., 2013; Zhang et al., 2015),
16
17 remained unchanged after DT treatment. Thus, SV damage is unlikely. Another possibility is
18
19 that changes in peripheral organs may affect HCs and cause secondary degeneration. We
20
21 systemically injected DT in this study, which could induce some unexpected side effects in
22
23 peripheral organs. Some previous studies reported lethality (Bonventre et al., 1973; Goldwich
24
25 et al., 2012; Christiaansen et al., 2014), weight loss (Meyer Zu Horste et al., 2010; Goldwich et
26
27 al., 2012; Christiaansen et al., 2014), proteinuria (Goldwich et al., 2012), and lung
28
29 inflammation (Chapman and Georas, 2013) as side effects of DT although molecular
30
31 mechanisms underlying these phenotypes were unknown. These organ disorders and/or
32
33 systemic disorders may affect HCs. DT ototoxicity was significant at P7 and P14 (Fig. 1 and 2),
34
35 when the cochlea matures toward the onset of hearing by remodeling structures and changing
36
37 gene expressions (Mikaelian and Ruben, 1965; Rubel and Fay, 2012; Walters and Zuo, 2013).
38
39 DT could greatly affect HCs undergoing maturation in an indirect manner.
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55

56 In conclusion, HCs are vulnerable cells that can be damaged by aging, environmental stress,
57
58 infection, some ototoxic drugs, and also unknown factors (Furness, 2015). DT toxicity on HCs
59
60
61
62
63
64
65

1 should be taken into consideration, and exploring the mechanisms is crucial for preventing HC
2
3 loss. The existence of a critical period in DT toxicity may provide clues to address this issue. In
4
5 addition, the present results demonstrate that phenotypes in otic or sound-associated behaviors
6
7
8 should be interpreted with caution when researchers use the DT-DTR system in juvenile mice.
9

10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Acknowledgments

We are grateful to Mr. K. Itakura (Nagoya University Graduate School of Medicine) and Mr. H. Takase (Nagoya City University Graduate School of Medicine) for scanning electron microscopy, Mr. T. Yoshimoto for H&E staining, Ms. Y. Itai, and M. Okamoto for their technical assistance, and Ms. A. Asano for secretarial work. The scanning electron microscope was used in the Laboratory of Division for Medical Research Engineering, Nagoya University Graduate School of Medicine. This work was partly supported by KAKENHI (Grants-in-Aid for Scientific Research on Priority Areas “Brain Environment” 231111007 to H. Kiyama, “Grants-in-Aid for Young Scientist (B)” 25830050 and “Grant-in-Aid for Scientific Research (C)” 16K07055 to H. Konishi, and “Grants-in-Aid for Scientific Research on Innovative Areas” 16H01639 to N. O.) from the Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan.

Author contributions

H. Konishi, N.O., T.N., S.U., K.Y., M.K and H. Kiyama designed the research. H. Konishi, N.O., A.M., Y.K., Y.A., M.K. performed the experiments. H. Konishi and H. Kiyama wrote the paper.

REFERENCES

- 1
2
3 Bonventre PF, Saelinger CB, Imhoff JG (1973) Studies on the effect of diphtheria toxin on
4
5 protein synthesis in mice. *J Med Microbiol* 6:169-176.
6
7
8 Cha JH, Brooke JS, Eidels L (1998) Toxin binding site of the diphtheria toxin receptor: loss and
9
10 gain of diphtheria toxin binding of monkey and mouse heparin-binding, epidermal
11
12 growth factor-like growth factor precursors by reciprocal site-directed mutagenesis.
13
14
15 *Mol Microbiol* 29:1275-1284.
16
17
18 Chapman TJ, Georas SN (2013) Adjuvant effect of diphtheria toxin after mucosal
19
20 administration in both wild type and diphtheria toxin receptor engineered mouse strains.
21
22
23
24 *J Immunol Methods* 400-401:122-126.
25
26
27 Christiaansen AF, Boggiatto PM, Varga SM (2014) Limitations of Foxp3(+) Treg depletion
28
29 following viral infection in DEREK mice. *J Immunol Methods* 406:58-65.
30
31
32 Collier RJ, Kandel J (1971) Structure and activity of diphtheria toxin. I. Thiol-dependent
33
34 dissociation of a fraction of toxin into enzymically active and inactive fragments. *J Biol*
35
36
37 *Chem* 246:1496-1503.
38
39
40 Cox BC, Chai R, Lenoir A, Liu Z, Zhang L, Nguyen DH, Chalasani K, Steigelman KA, Fang J,
41
42 Rubel EW, Cheng AG, Zuo J (2014) Spontaneous hair cell regeneration in the neonatal
43
44 mouse cochlea in vivo. *Development* 141:816-829.
45
46
47 Dorland RB, Middlebrook JL, Leppla SH (1979) Receptor-mediated internalization and
48
49 degradation of diphtheria toxin by monkey kidney cells. *J Biol Chem* 254:11337-11342.
50
51
52
53 Furness DN (2015) Molecular basis of hair cell loss. *Cell Tissue Res* 361:387-399.
54
55
56 Gill DM, Dinius LL (1971) Observations on the structure of diphtheria toxin. *J Biol Chem*
57
58
59 246:1485-1491.
60
61
62
63
64
65

1 Goldwich A, Steinkasserer A, Gessner A, Amann K (2012) Impairment of podocyte function
2
3 by diphtheria toxin--a new reversible proteinuria model in mice. *Lab Invest*
4
5
6 92:1674-1685.
7

8 Han JH, Kushner SA, Yiu AP, Hsiang HL, Buch T, Waisman A, Bontempi B, Neve RL,
9
10 Frankland PW, Josselyn SA (2009) Selective erasure of a fear memory. *Science*
11
12
13 323:1492-1496.
14
15

16 Honjo T, Nishizuka Y, Hayaishi O (1968) Diphtheria toxin-dependent adenosine diphosphate
17
18 ribosylation of aminoacyl transferase II and inhibition of protein synthesis. *J Biol Chem*
19
20
21 243:3553-3555.
22
23

24 Hu L, Lu J, Chiang H, Wu H, Edge AS, Shi F (2016) Diphtheria Toxin-Induced Cell Death
25
26 Triggers Wnt-Dependent Hair Cell Regeneration in Neonatal Mice. *J Neurosci*
27
28
29 36:9479-9489.
30
31

32 Hunter-Duvar IM (1978) A technique for preparation of cochlear specimens for assessment
33
34 with the scanning electron microscope. *Acta Otolaryngol Suppl* 351:3-23.
35
36

37 Knowlton WM, Palkar R, Lippoldt EK, McCoy DD, Baluch F, Chen J, McKemy DD (2013) A
38
39 sensory-labeled line for cold: TRPM8-expressing sensory neurons define the cellular
40
41
42 basis for cold, cold pain, and cooling-mediated analgesia. *J Neurosci* 33:2837-2848.
43
44

45 Kurioka T, Lee MY, Heeringa AN, Beyer LA, Swiderski DL, Kanicki AC, Kabara LL, Dolan
46
47 DF, Shore SE, Raphael Y (2016) Selective hair cell ablation and noise exposure lead to
48
49
50 different patterns of changes in the cochlea and the cochlear nucleus. *Neuroscience*
51
52
53 332:242-257.
54
55

56 Kwon SJ, Lee GT, Lee JH, Iwakura Y, Kim WJ, Kim IY (2014) Mechanism of pro-tumorigenic
57
58 effect of BMP-6: neovascularization involving tumor-associated macrophages and
59
60
61

1 IL-1a. Prostate 74:121-133.

2
3 Mahrt EJ, Perkel DJ, Tong L, Rubel EW, Portfors CV (2013) Engineered deafness reveals that
4
5 mouse courtship vocalizations do not require auditory experience. J Neurosci
6
7
8 33:5573-5583.
9

10
11 Meyer Zu Horste G, Zozulya AL, El-Haddad H, Lehmann HC, Hartung HP, Wiendl H,
12
13 Kieseier BC (2010) Active immunization induces toxicity of diphtheria toxin in
14
15 diphtheria resistant mice--implications for neuroinflammatory models. J Immunol
16
17
18 Methods 354:80-84.
19

20
21 Mikaelian D, Ruben RJ (1965) Development of hearing in the normal Cba-J mouse: correlation
22
23 of physiological observations with behavioral responses and with cochlear anatomy.
24
25
26 Acta oto-laryngologica 59:451-461.
27

28
29 Mitamura T, Higashiyama S, Taniguchi N, Klagsbrun M, Mekada E (1995) Diphtheria toxin
30
31 binds to the epidermal growth factor (EGF)-like domain of human heparin-binding
32
33 EGF-like growth factor/diphtheria toxin receptor and inhibits specifically its mitogenic
34
35 activity. J Biol Chem 270:1015-1019.
36
37

38
39 Naglich JG, Metherall JE, Russell DW, Eidels L (1992) Expression cloning of a diphtheria
40
41 toxin receptor: identity with a heparin-binding EGF-like growth factor precursor. Cell
42
43
44 69:1051-1061.
45
46

47
48 Nakashima T, Pyykko I, Arroll MA, Casselbrant ML, Foster CA, Manzoor NF, Megerian CA,
49
50
51 Naganawa S, Young YH (2016) Meniere's disease. Nat Rev Dis Primers 2:16028.
52

53
54 Noben-Trauth K, Zheng QY, Johnson KR (2003) Association of cadherin 23 with polygenic
55
56 inheritance and genetic modification of sensorineural hearing loss. Nat Genet 35:21-23.
57

58
59 Ohgami N, Ida-Eto M, Shimotake T, Sakashita N, Sone M, Nakashima T, Tabuchi K, Hoshino
60

1 T, Shimada A, Tsuzuki T, Yamamoto M, Sobue G, Jijiwa M, Asai N, Hara A,
2
3 Takahashi M, Kato M (2010) c-Ret-mediated hearing loss in mice with Hirschsprung
4
5 disease. Proc Natl Acad Sci U S A 107:13051-13056.
6
7
8 Ohlemiller KK, Dahl AR, Gagnon PM (2010) Divergent aging characteristics in CBA/J and
9
10 CBA/CaJ mouse cochleae. J Assoc Res Otolaryngol 11:605-623.
11
12
13 Pappenheimer AM, Jr., Harper AA, Moynihan M, Brockes JP (1982) Diphtheria toxin and
14
15 related proteins: effect of route of injection on toxicity and the determination of
16
17 cytotoxicity for various cultured cells. J Infect Dis 145:94-102.
18
19
20
21 Parker M, Brugeaud A, Edge AS (2010) Primary culture and plasmid electroporation of the
22
23 murine organ of Corti. J Vis Exp.
24
25
26
27 Parkhurst CN, Yang G, Ninan I, Savas JN, Yates JR, 3rd, Lafaille JJ, Hempstead BL, Littman
28
29 DR, Gan WB (2013) Microglia promote learning-dependent synapse formation through
30
31 brain-derived neurotrophic factor. Cell 155:1596-1609.
32
33
34
35 Patuzzi R (2011) Ion flow in stria vascularis and the production and regulation of cochlear
36
37 endolymph and the endolymphatic potential. Hear Res 277:4-19.
38
39
40 Pedersen J, Ugleholdt RK, Jorgensen SM, Windelov JA, Grunddal KV, Schwartz TW,
41
42 Fuchtbauer EM, Poulsen SS, Holst PJ, Holst JJ (2013) Glucose metabolism is altered
43
44 after loss of L cells and alpha-cells but not influenced by loss of K cells. Am J Physiol
45
46 Endocrinol Metab 304:E60-73.
47
48
49
50
51 Robinson EA, Henriksen O, Maxwell ES (1974) Elongation factor 2. Amino acid sequence at
52
53 the site of adenosine diphosphate ribosylation. J Biol Chem 249:5088-5093.
54
55
56 Rubel EW, Fritsch B (2002) Auditory system development: primary auditory neurons and
57
58 their targets. Annu Rev Neurosci 25:51-101.
59
60
61
62
63
64
65

1 Rubel EW, Fay RR (2012) Development of the auditory system: Springer Science & Business
2
3 Media.

4
5 Saito M, Iwawaki T, Taya C, Yonekawa H, Noda M, Inui Y, Mekada E, Kimata Y, Tsuru A,
6
7 Kohno K (2001) Diphtheria toxin receptor-mediated conditional and targeted cell
8
9 ablation in transgenic mice. *Nat Biotechnol* 19:746-750.

10
11 Schechterson LC, Bothwell M (1994) Neurotrophin and neurotrophin receptor mRNA
12
13 expression in developing inner ear. *Hear Res* 73:92-100.

14
15 Song Y, Xia A, Lee HY, Wang R, Ricci AJ, Oghalai JS (2015) Activity-dependent regulation
16
17 of prestin expression in mouse outer hair cells. *J Neurophysiol* 113:3531-3542.

18
19 Tong L, Strong MK, Kaur T, Juiz JM, Oesterle EC, Hume C, Warchol ME, Palmiter RD, Rubel
20
21 EW (2015) Selective deletion of cochlear hair cells causes rapid age-dependent changes
22
23 in spiral ganglion and cochlear nucleus neurons. *J Neurosci* 35:7878-7891.

24
25 Walters BJ, Zuo J (2013) Postnatal development, maturation and aging in the mouse cochlea
26
27 and their effects on hair cell regeneration. *Hear Res* 297:68-83.

28
29 Wang H, Melton DW, Porter L, Sarwar ZU, McManus LM, Shireman PK (2014) Altered
30
31 macrophage phenotype transition impairs skeletal muscle regeneration. *Am J Pathol*
32
33 184:1167-1184.

34
35 Wang J, Tymczynsyn N, Yu Z, Yin S, Bance M, Robertson GS (2011) Overexpression of
36
37 X-linked inhibitor of apoptosis protein protects against noise-induced hearing loss in
38
39 mice. *Gene Ther* 18:560-568.

40
41 Willott JF (1986) Effects of aging, hearing loss, and anatomical location on thresholds of
42
43 inferior colliculus neurons in C57BL/6 and CBA mice. *J Neurophysiol* 56:391-408.

44
45 Xu M, Kobets A, Du JC, Lennington J, Li L, Banasr M, Duman RS, Vaccarino FM, DiLeone
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1 RJ, Pittenger C (2015) Targeted ablation of cholinergic interneurons in the dorsolateral
2 striatum produces behavioral manifestations of Tourette syndrome. Proc Natl Acad Sci
3 U S A 112:893-898.
4
5
6
7

8 Zhang F, Dai M, Neng L, Zhang JH, Zhi Z, Fridberger A, Shi X (2013) Perivascular
9 macrophage-like melanocyte responsiveness to acoustic trauma--a salient feature of
10 strial barrier associated hearing loss. Faseb J 27:3730-3740.
11
12
13
14
15

16 Zhang J, Chen S, Hou Z, Cai J, Dong M, Shi X (2015) Lipopolysaccharide-induced middle ear
17 inflammation disrupts the cochlear intra-strial fluid-blood barrier through
18 down-regulation of tight junction proteins. PLoS One 10:e0122572.
19
20
21
22
23

24 Zhang W, Dai M, Fridberger A, Hassan A, Degagne J, Neng L, Zhang F, He W, Ren T, Trune D,
25 Auer M, Shi X (2012) Perivascular-resident macrophage-like melanocytes in the inner
26 ear are essential for the integrity of the intrastrial fluid-blood barrier. Proc Natl Acad Sci
27 U S A 109:10388-10393.
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

FIGURE LEGENDS

Fig. 1. Permanent hearing loss in C57BL/6 mice administrated with DT at P7.

(A) Representative ABR waveforms at 0, 20, 40, 60, and 80 dB SPL of 12 kHz sound in P21. No waveform was observed under 60 dB SPL in DT-administrated mice. (B) ABR threshold of 4, 12, 20, and 32 kHz sounds at P21 (PBS: n = 4; DT: n = 5). #: number of scale-out animals. * $P < 0.05$, ** $P < 0.001$; two-tailed unpaired Student's t -test. (C) ABR threshold of 4, 12, 20, and 32 kHz sounds at 8W (PBS: n = 4; DT: n = 5). The same animals used in B were allowed to mature to 8W and analyzed. #: number of scale-out animals. * $P < 0.05$, ** $P < 0.001$; two-tailed unpaired Student's t -test.

Fig. 2. Juvenile C57BL/6 mice are vulnerable to DT.

ABR threshold of 4, 12, 20, and 32 kHz sounds at 14 or 15 days after PBS and DT administration. (A) Administration at P14 and analysis at P28 (PBS: n = 5; DT: n = 5). #: number of scale-out animals. * $P < 0.05$, ** $P < 0.001$; two-tailed unpaired Student's t -test. (B) Administration at P28 and analysis at P43 (PBS: n = 5; DT: n = 5). No significance was observed at all frequencies. (C) Administration at 8W and analysis at 10W (14 days later) (PBS: n = 5; DT: n = 5). No significance was observed at all frequencies.

Fig. 3. Degeneration of SGNs and HCs after DT administration at P7 in C57BL/6 mice.

(A) Sections of the cochlear middle turn with H&E staining at P21 and 8W. Insets show higher magnifications of the organ of Corti. An arrow and an arrowhead indicate IHC and OHC, respectively. Scale bar = 100 μm and 30 μm (insets). (B) Density of SGNs in the apical, middle and basal turn at P21 and 8W (n = 3). Values show mean \pm S.E.M. * $P < 0.05$, ** $P < 0.005$;

1 two-tailed unpaired Student's *t*-test. (C) Whole-mount TNBT staining of HCs in the apical,
2 middle and basal turn at P21. Scale bar = 50 μm (D) Number of IHCs and OHCs in apical,
3 middle, and basal turn of cochlea at P21 (n = 5). Values show mean \pm S.E.M. **P* < 0.05, ***P* <
4 0.001; two-tailed unpaired Student's *t*-test. (E) IHC and OHC degeneration in the middle turn
5 determined by SEM. Arrows show degenerated HCs. Scale bar = 10 μm .
6
7
8
9
10
11
12
13
14
15

16 **Fig. 4. Time-course of HC degeneration in the middle turn of C57BL/6 mice.**

17 Mice administered with PBS (A–C, G–I and M–O) and DT (D–F, J–L and P–R) at P7 were
18 analyzed by SEM at P8 (A–F), P10 (G–L) and P14 (M–R). Areas indicated by red squares
19 were shown as higher magnification images. Higher magnification of IHCs: B, E, H, K, N and
20 Q. Higher magnification of OHCs: C, F, I, L, O and R. Arrows show degenerated HCs. An
21 arrowhead in J (shown in L as a high magnification image) shows a putative degenerating cell.
22 Scale bar = 10 μm (A, D, G, J, M and P) and 2 μm (B, C, E, F, H, I, K, L, N, O, Q and R).
23
24
25
26
27
28
29
30
31
32
33
34
35
36

37 **Fig. 5. DT ototoxicity in juvenile CBA/J mice.**

38 CBA/J mice administered PBS and DT at P7 were analyzed at P21. (A) ABR threshold of 4, 12,
39 20, and 32 kHz sounds (PBS: n = 4; DT: n = 5). Note that there were no scale-out animals in
40 contrast to Fig. 1. **P* < 0.05, ***P* < 0.001; two-tailed unpaired Student's *t*-test. (B) IHC and
41 OHC degeneration in the middle turn as determined by SEM. Arrows show degenerated HCs.
42
43
44
45
46
47
48
49
50
51 Scale bar = 10 μm .
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Figure 1. Konishi et al.




Figure 2. Konishi et al.




Figure 3. Konishi et al.




Figure 4. Konishi et al.




Figure 5. Konishi et al.

